The physiological relevance of downstream effectors of p53 activity
Abstract
The TP53 tumor suppressor encodes a transcription factor that regulates the expression of hundreds of target genes. Previous mouse studies have identified a conserved p53-dependent transcriptional signature that includes Cdkn1A (p21) , Gtse1 ( G2 and S-phase expressed 1 ), and Eda2r . In this study, we investigated the physiological roles of these three genes, along with Bbc3 (Puma), a p53 target involved in apoptosis, as effectors of p53 activity. We generated alleles of Gtse1 and Eda2r . In contrast to previously reported Cdkn1A-null and Bbc3-null mice which do not exhibit any overt phenotypes, mice expressing N-terminal deletions of Gtse1 ( Gtse1Δ7 ) and Eda2r ( Eda2rΔ11 ) displayed defects in spermatogenesis and liver abnormalities, respectively. We crossed these mice to an Mdm2 -deletion model that constitutively activates p53 resulting in multiple phenotypes and lethality. Notably, loss of p21 rescued the lethality associated with constitutive p53 activation in vivo, whereas the Gtse1Δ7 mutant partially rescued this effect; no rescue was observed with Eda2rΔ11 or Bbc3 loss. These findings indicate that cell cycle regulators, rather than apoptosis-related genes, are the main drivers of sustained p53-induced gastrointestinal defects and lethality.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (7)
Vinod Pant
Department of Genetics, The University of Texas MD Anderson Cancer Center
Sydney M. Moyer
Department of Genetics, The University of Texas MD Anderson Cancer Center
Mitheera V
Department of Genetics, The University of Texas MD Anderson Cancer Center
Amanda R. Wasylishen
Department of Genetics, The University of Texas MD Anderson Cancer Center
Akshita Mirani
Department of Genetics, The University of Texas MD Anderson Cancer Center
Natalie Fowlkes
Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center
Guillermina Lozano
Department of Genetics, The University of Texas MD Anderson Cancer Center